The 2-Minute Rule for AZ191
DYRK1B kinase not too long ago emerged as a possible goal in most cancers, metabolic syndrome, and nonalcoholic fatty liver ailment, but the lack of structural information hinders the design of selective DYRK1B inhibitors. In this article, we offer a way for recombinant production, action assays, crystallization circumstances in addition to a large